Phase II study evaluating the toxicity and activity of the combination lapatinib + capecitabine in elderly patients aged 70 and over with metastatic breast cancer over expressing HER2.
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2014
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 03 Sep 2013 Planned end date changed from 8 Dec 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.